PMID- 15585438
OWN - NLM
STAT- MEDLINE
DCOM- 20050126
LR  - 20051116
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 24
IP  - 12
DP  - 2004 Dec
TI  - Dosing of unfractionated heparin in acute coronary syndromes.
PG  - 1681-91
AB  - Although the use of low-molecular-weight heparins for treatment of acute coronary 
      syndromes (ACS) has increased in recent years, unfractionated heparin (UFH) 
      remains the drug of choice for many patients and institutions. One reason is that 
      this agent is safe for patients with renal dysfunction as well as those who 
      undergo percutaneous coronary intervention or coronary artery bypass graft. The 
      use of UFH is complicated by the increased risk of bleeding due to concurrent 
      administration of numerous antiplatelet drugs in most patients with ACS, the 
      limited data regarding ideal therapeutic range, and the wide variability of 
      patient response. Knowledge regarding the optimal therapeutic range and how to 
      achieve it efficiently may enable clinicians to improve clinical outcomes in 
      patients with ACS. We reviewed and analyzed the available evidence to clarify how 
      to best manage UFH therapy in patients with ACS. Current data support the use of 
      a lower and narrower therapeutic range for patients with ACS than the range that 
      is used for venous thromboembolism. Many factors in addition to weight affect 
      patient response to UFH, including age, sex, diabetes mellitus, smoking status, 
      and obesity.
FAU - Badawi, Omar
AU  - Badawi O
AD  - Department of Pharmacy Practice and Science, School of Pharmacy, University of 
      Maryland, Baltimore, Maryland 21201, USA. obadawi@rx.umaryland.edu
FAU - Oyen, Lance J
AU  - Oyen LJ
FAU - Haines, Stuart T
AU  - Haines ST
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Acute Disease
MH  - Body Weight
MH  - Coronary Disease/*drug therapy/physiopathology
MH  - Heparin/*administration & dosage/pharmacokinetics
MH  - Humans
MH  - Prospective Studies
MH  - Retrospective Studies
RF  - 50
EDAT- 2004/12/09 09:00
MHDA- 2005/01/27 09:00
CRDT- 2004/12/09 09:00
PHST- 2004/12/09 09:00 [pubmed]
PHST- 2005/01/27 09:00 [medline]
PHST- 2004/12/09 09:00 [entrez]
AID - 10.1592/phco.24.17.1681.52349 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2004 Dec;24(12):1681-91. doi: 10.1592/phco.24.17.1681.52349.